Gumus, EdaBingol, HalukZor, Erhan2024-02-232024-02-2320230731-70851873-264Xhttps://doi.org/10.1016/j.jpba.2022.115206https://hdl.handle.net/20.500.12452/12259Early diagnosis saves lives in many diseases. In this sense, monitoring of biomarkers is crucial for the diagnosis of diseases. Lateral flow assays (LFAs) have attracted great attention among paper-based point-of-care testing (POCT) due to their low cost, user-friendliness, and time-saving advantages. Developments in the field of health have led to an increase of interest in these rapid tests. LFAs are used in the diagnosis and monitoring of many diseases, thanks to biomarkers that can be observed in body fluids. This review covers the recent advances dealing with the design and strategies for the development of LFA for the detection of biomarkers used in clinical applications in the last 5 years. We focus on various strategies such as choosing the nanoparticle type, single or multiple test approaches, and equipment for signal transducing for the detection of the most common biomarkers in different diseases such as cancer, cardiovascular, infectious, and others including Parkinson's and Alzheimer's diseases. We expect that this study will contribute to the different approaches in LFA and pave the way for other clinical applications.eninfo:eu-repo/semantics/closedAccessLateral Flow AssayBiomarker DetectionPoint Of CareDiseaseArticle225365863822-s2.0-85145314862Q2WOS:000913449500001Q210.1016/j.jpba.2022.115206